// App-Quantinova.ai

AB0532 (2021) : MAINTENANCE OF RESPONSE THROUGH 5 YEARS OF CONTINUOUS GUSELKUMAB TREATMENT: RESULTS FROM THE PHASE-3 VOYAGE 1 TRIAL

Researchers

Presenter

  • C. E. M. Griffiths

Principal Investigators

  • K. Papp

  • M. Song

  • M. Miller

  • Y. You

  • Y. K. Shen

  • A. Blauvelt

Medical Centers

  • NIHR Manchester Biomedical Research Centre, University of Manchester, Dermatology Centre, Manchester, United Kingdom

  • Salford Royal NHS Foundation Trust, Dermatology Department, Salford, United Kingdom

  • K. Papp Clinical Research, Department of Dermatology, Waterloo, Ontario, Canada

  • Probity Research Inc., Clinical Research, Waterloo, Ontario, Canada

  • Janssen Research and Development, LLC, Department of Immunology, San Diego, CA, United States of America

  • Janssen Research & Development, LLC, Clinical Biostats, Spring House, Pennsylvania, United States of America

  • Oregon Medical Research Center, Dermatology, Portland, United States of America

Locations

  • United Kingdom

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Open Label

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved